SCHEMBL1997164

SCHEMBL1997164

O=Cc1ccc(-c2ccccc2CO)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 3/20 0.51
DRD2 P14416 1/20 0.51
DRD4 P21917 1/20 0.51
DRD5 P21918 1/20 0.51
DRD3 P35462 1/20 0.51
ALDH1A1 P00352 2/20 0.43
PDCD1 Q15116 1/20 0.43
CD274 Q9NZQ7 1/20 0.43
CYP2A6 P11509 1/20 0.43
PDK2 Q15119 1/20 0.42
KMT2A Q03164 1/20 0.42
FOLH1 Q04609 2/20 0.40
ALDH5A1 P51649 1/20 0.40
ABAT P80404 1/20 0.40
LTB4R2 Q9NPC1 1/20 0.40
DPP4 P27487 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
CHEK1 O14757 1/20 0.39
NAT1 P18440 1/20 0.37
PTGS1 P23219 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3858145 0.82 PTGS2 (0.48) DRD1DRD2DRD4DRD5DRD3
SCHEMBL1666926 0.81 DRD1 (0.60) DRD1DRD2DRD4DRD5DRD3
SCHEMBL29733609 0.79 DRD1 (0.58) DRD1DRD2DRD4DRD5DRD3
SCHEMBL29733602 0.79 DRD1 (0.58) DRD1DRD2DRD4DRD5DRD3
SCHEMBL7195098 0.79 HRH3 (0.54) DRD1DRD2DRD4DRD5DRD3
SCHEMBL28758533 0.78 PDCD1 (0.41) DRD1DRD2DRD4DRD5DRD3
SCHEMBL1919862 0.77 DRD1 (0.46) DRD1DRD2DRD4DRD5DRD3
SCHEMBL35966 0.77 ALDH1A1 (0.59) DRD1DRD2DRD4DRD5DRD3
SCHEMBL7951583 0.77 PDCD1 (0.61) ALDH1A1PDCD1CD274CYP2A6PDK2
SCHEMBL117091 0.77 PDCD1 (0.65) ALDH1A1PDCD1CD274CYP2A6PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 DRD1 100/4885DRD2 97/4885DRD4 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.